Vijaya Diagnostic Centre Ltd
VIJAYAVijaya Diagnostic Centre Ltd is strength at full price. The numbers are improving — and a P/E at the 92nd percentile of its own range says the market knows.
The sharpest disagreement: the engine is strong, but at the 92nd percentile of its own range you are paying full price for it.
The price is in a confirmed uptrend (12 weeks in) while the P/E sits at the 92nd percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +37.1% year on year, and 155% of the last 3 years' profit arrived as cash. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Vijaya Diagnostic Centre Ltd trades at ₹1,344, in a confirmed uptrend and 12 weeks into that stage. That is +17.3% against its own 200-day average. It sits at 91% of a 52-week range of ₹870 to ₹1,389. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (3 weeks and counting).
Today the stock is in a confirmed uptrend — week 12 of stage 2, confirmed. At ₹1,344 it trades +17.3% versus its 200-day average and sits at 91% of its 52-week range (₹870–₹1,389).
Against the market, two honest reads. Cumulative: over the last 4.9 years the stock moved +114% while the NIFTY 500 moved +57% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-07-10) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Vijaya Diagnostic Centre Ltd trades at 80.0× P/E, at the pricey end of its own range (92nd percentile). Its long-run median P/E is 61.9×, measured across 4.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 80.0× is at the pricey end of its own range (92nd percentile), against a long-run median of 61.9× measured over 4.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +20.6% against a +24.1% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +16.5%/yr price move, ~−2.0%/yr came from earnings growth and ~+18.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Vijaya Diagnostic Centre Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 21.3% and holding. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +19.5% | +21.0% | +16.6% | — |
| Profit | +20.1% | +26.7% | +15.3% | — |
| EPS | +20.6% | +26.6% | −2.0% | — |
| Share price | +24.1% | +43.7% | +16.5% | — |
4-Factor Sector Score
58.8/100 — rank 5 of 9 in Diagnostics · 96% evidence confidence
Vijaya Diagnostic Centre Ltd scores 58.8 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 5. Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
The four contributions add to the total exactly: 20.1 + 18.5 + 6.4 + 13.8 = 58.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Vijaya Diagnostic Centre Ltd reported ₹219 Cr of revenue in the Mar 26 quarter, +26.6% year on year. That is the 12th straight quarter of year-on-year growth. Over 8 years it has compounded at 15.8% a year. The last full year, FY26, came in at ₹814 Cr. The last four reported quarters add to ₹814 Cr.
FY26 revenue came in at ₹814 Cr (+19.5% on the year), capping 8 years at 15.8% compound. The latest quarter (Mar 26) printed ₹219 Cr, +26.6% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +19.7% growth against the decade's 15.8% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +19.5% over the last 4 quarters against +21.9%/yr over the last 8 — stabilising; TTM profit +20.1% vs +20.1%/yr — stabilising.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Vijaya Diagnostic Centre Ltd's operating margin is 44.0% in the Mar 26 quarter, +4.0 percentage points against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 32.0% to 44.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 44.0%, +4.0 pp against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 32.0%–44.0%.
Why the margin moved: operating margin went +3.8 pp year on year while gross margin went +1.4 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Vijaya Diagnostic Centre Ltd earned ₹48.0 Cr of net profit in the Mar 26 quarter, +37.1% year on year. It is the 12th consecutive quarter of growth. Full-year FY26 profit was ₹173 Cr. The 8-year compound rate is 22.1%. That is 21.9% of the quarter's revenue. The same quarter a year earlier earned ₹35.0 Cr.
Mar 26 profit was ₹48.0 Cr, +37.1% year on year — the 12th consecutive quarter of growth. On the full year, FY26 printed ₹173 Cr (+20.1%), and the 8-year compound rate is 22.1%.
Why profit moved: revenue contributed +26.6% and the margin +4.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +21.1% vs revenue +19.7%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 155% of Vijaya Diagnostic Centre Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹271 Cr of operating cash against ₹173 Cr of profit. After ₹261 Cr of capital spending, ₹10.0 Cr was left as free cash.
FY26: operating cash of ₹271 Cr against reported profit of ₹173 Cr, leaving free cash of ₹10.0 Cr after ₹261 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 155% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 155%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 3.5× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Vijaya Diagnostic Centre Ltd's cash conversion cycle runs −117 days in FY26, up from −118 days in FY21. Capital spending ran ₹772 Cr over the last 3 years. At FY26 sales of ₹814 Cr each day of that cycle holds about ₹2.2 Cr, so roughly ₹−261 Cr sits inside the business at any moment.
FY26: debtors at 9 days, inventory at 19 days — roughly 0.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −117 days, looser than FY21's −118.
The full loop: cash goes out to suppliers and production on day 0; stock waits 19 days to sell; customers pay about 9 days after that; and suppliers themselves are paid at 145 days — netting out to the −117-day cycle.
In money terms: at FY26 sales of ₹814 Cr, each day of the cycle holds about ₹2.2 Cr — so the −117-day loop keeps roughly ₹−261 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹772 Cr over the last 3 fiscal years against ₹220 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹34.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Vijaya Diagnostic Centre Ltd earns a ROCE of 21% in FY26. That is up from a trough of 18% in FY23. Return on invested capital clears the cost of that capital by +6.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 21.3% net margin on 0.54× asset turns.
FY26 ROCE is 21%, recovered from a FY23 trough of 18% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 21.3% net margin × 0.54× asset turns × 1.57× balance-sheet leverage ≈ 18.1% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 18.0% − 12.0% = a +6.0 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Vijaya Diagnostic Centre Ltd carries total debt of ₹423 Cr against shareholder equity of ₹957 Cr as of Mar 26, a debt-to-equity of 0.44. On the annual view that ratio went from 0.39 in FY22 to 0.44 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹423 Cr against shareholder equity of ₹957 Cr — a debt-to-equity of 0.44. On the annual view, debt-to-equity went from 0.39 (FY22) to 0.44 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 10.1 points of Vijaya Diagnostic Centre Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 31.6% of the company. Foreign institutions moved −8.4 points over the same window, to 11.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +10.1 points over 8 quarters to 31.6%; Foreign institutions: −8.4 points over 8 quarters to 11.7%; Promoters: −1.4 points over 8 quarters to 52.5%.
Why the register moved: rotation — foreign institutions −8.4 points against domestic institutions +10.1 points over 8 quarters, with promoters −1.4 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Vijaya Diagnostic Centre Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Thyrocare Technologies LtdTHYROCARE | 77.4/100Favorable setup100% evidence | LEADER | 27.9/35 Revenue 21.3% · PAT 67.6% · OPM change 2 pp 100% evidence | 18.1/25 ROCE 35.4% · OPM 32% 100% evidence | 12.0/20 P/E 51× · PEG 1.1 100% evidence | 19.4/20 RS sector 16.8% · RS bench 27.8% · 1Y 32.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.9 + 18.1 + 12 + 19.4 = 77.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Dr Lal Pathlabs LtdLALPATHLAB | 63.3/100Mixed-positive evidence100% evidence | LEADER | 14.6/35 Revenue 14.3% · PAT 5% · OPM change 2 pp 100% evidence | 16.8/25 ROCE 28% · OPM 31% 100% evidence | 13.0/20 P/E 56.8× · PEG 1.29 100% evidence | 18.9/20 RS sector 11.6% · RS bench 22.5% · 1Y 23.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 16.8 + 13 + 18.9 = 63.3 · Decision use: Price leads the evidence: RS versus the benchmark is 22.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 3Metropolis Healthcare LtdMETROPOLIS | 60.1/100Mixed-positive evidence96% evidence | LEADER | 27.2/35 Revenue 23.7% · PAT 31.7% · OPM change 7 pp 88% evidence | 11.7/25 ROCE 17.8% · OPM 25% 100% evidence | 6.3/20 P/E 62.3× · PEG 2.4 100% evidence | 14.9/20 RS sector 4.3% · RS bench 14.4% · 1Y 18.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 11.7 + 6.3 + 14.9 = 60.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4One Global Service Provider Ltd514330 | 59.8/100Mixed-positive evidence78% evidence | TURNING | 24.9/35 Revenue 100% · PAT 100% · OPM change -8 pp 83% evidence | 16.5/25 ROCE 87% · OPM 18% 76% evidence | 10.1/20 P/E 15.9× · PEG — 50% evidence | 8.3/20 RS sector 1.3% · RS bench 10.9% · 1Y 121.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 16.5 + 10.1 + 8.3 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Vijaya Diagnostic Centre Ltdthis pageVIJAYA | 58.8/100Mixed-positive evidence96% evidence | LEADER | 20.1/35 Revenue 19.5% · PAT 20.1% · OPM change 4 pp 88% evidence | 18.5/25 ROCE 21.3% · OPM 44% 100% evidence | 6.4/20 P/E 80× · PEG 1.46 100% evidence | 13.8/20 RS sector 11.3% · RS bench 21.8% · 1Y 25.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 18.5 + 6.4 + 13.8 = 58.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 63B Blackbio DX Ltd3BBLACKBIO | 48.6/100Mixed-negative evidence83% evidence | TURNING | 15.2/35 Revenue 47.1% · PAT 25.7% · OPM change -11.2 pp 83% evidence | 15.8/25 ROCE 25.5% · OPM 24% 95% evidence | 11.8/20 P/E 18.3× · PEG — 50% evidence | 5.8/20 RS sector -17.6% · RS bench -9.3% · 1Y -13.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 15.8 + 11.8 + 5.8 = 48.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Krsnaa Diagnostics LtdKRSNAA | 43.0/100Mixed-negative evidence77% evidence | ASLEEP | 13.4/35 Revenue 7.8% · PAT 30.8% · OPM change 0 pp 83% evidence | 10.5/25 ROCE 12.7% · OPM 28% 95% evidence | 14.6/20 P/E 16.9× · PEG — 50% evidence | 4.5/20 RS sector -18.5% · RS bench -23.4% · 1Y -38.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 13.4 + 10.5 + 14.6 + 4.5 = 43 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 8Suraksha Diagnostic LtdSURAKSHA | 39.0/100Mixed-negative evidence76% evidence | ASLEEP | 13.8/35 Revenue 23.1% · PAT 1.4% · OPM change 0.5 pp 83% evidence | 13.0/25 ROCE 17% · OPM 29.9% 95% evidence | 10.4/20 P/E 40.8× · PEG — 15% evidence | 1.8/20 RS sector -20.4% · RS bench -12.3% · 1Y -17.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 13 + 10.4 + 1.8 = 39 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Vimta Labs LtdVIMTALABS | 44.4/100Thin evidence · provisional45% evidence | TURNING | 17.5/35 Revenue 7.8% · PAT 48.8% · OPM change 5 pp 18% evidence | 13.5/25 ROCE 17.6% · OPM 37% 57% evidence | 7.5/20 P/E 44.8× · PEG — 50% evidence | 5.9/20 RS sector -21.9% · RS bench 4.8% · 1Y 4.1%7 of 10 weeks ahead 70% evidence |
| Exact sum: 17.5 + 13.5 + 7.5 + 5.9 = 44.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Vijaya Diagnostic Centre Ltd's share price today?
Vijaya Diagnostic Centre Ltd trades at ₹1,344, +24.1% over the past year. The company is valued at ₹13,847 Cr. The stock sits at 91% of its 52-week range of ₹870–₹1,389, +17.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 12 weeks in. — as of 31 July 2026.
What were Vijaya Diagnostic Centre Ltd's latest quarterly results?
Vijaya Diagnostic Centre Ltd reported revenue of ₹219 Cr and net profit of ₹48.0 Cr for the Mar 26 quarter. Revenue rose 26.6% and profit rose 37.1% year on year. Earnings per share were ₹4.66. The operating margin was 44.0%, 4.0 pp higher than a year earlier. — as of 31 July 2026.
What is Vijaya Diagnostic Centre Ltd's revenue?
Vijaya Diagnostic Centre Ltd reported revenue of ₹219 Cr in the Mar 26 quarter, +26.6% year on year. For the full FY26 fiscal year, revenue was ₹814 Cr (+19.5%). Over the last 8 years revenue compounded at 15.8% a year. — as of 31 July 2026.
What is Vijaya Diagnostic Centre Ltd's profit?
Vijaya Diagnostic Centre Ltd earned ₹48.0 Cr of net profit in the Mar 26 quarter, +37.1% year on year — the 12th straight quarter of growth. Full-year FY26 profit was ₹173 Cr. The operating margin ran 44.0% in the latest quarter. — as of 31 July 2026.
What is Vijaya Diagnostic Centre Ltd's market cap?
Vijaya Diagnostic Centre Ltd's market capitalisation is ₹13,847 Cr at a share price of ₹1,344. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Vijaya Diagnostic Centre Ltd's P/E ratio?
Vijaya Diagnostic Centre Ltd trades at a P/E of 80.0×, at the 92nd percentile of its own 5-year range, against a long-run median of 61.9×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Vijaya Diagnostic Centre Ltd pay a dividend?
Yes — Vijaya Diagnostic Centre Ltd's dividend payout was 12% of profit in FY26, and it recorded a payout in 5 of its last 9 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Vijaya Diagnostic Centre Ltd overvalued?
On its own history, Vijaya Diagnostic Centre Ltd looks expensive against its own history: its P/E of 80.0× sits at the 92nd percentile of its 5-year range (long-run median 61.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Vijaya Diagnostic Centre Ltd growing?
Yes — Vijaya Diagnostic Centre Ltd is growing: latest-quarter revenue +26.6% year on year, profit +37.1%, and the margin +4.0 pp at 44.0%. The 8-year compound rates are 15.8% (revenue) and 22.1% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Vijaya Diagnostic Centre Ltd performing?
Vijaya Diagnostic Centre Ltd is in a confirmed uptrend, 12 weeks in. Its latest quarter's revenue rose 26.6% and profit rose 37.1% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Vijaya Diagnostic Centre Ltd in?
Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 21.3% and holding. The read comes from the last 12 quarters of growth (revenue growth +19.5% latest, profit growth +20.1% latest, eps growth +20.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Vijaya Diagnostic Centre Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 12 of stage 2), trading +17.3% versus its 200-day average and at 91% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Vijaya Diagnostic Centre Ltd beating the market?
Not lately — on a trailing-13-week view Vijaya Diagnostic Centre Ltd is currently behind the NIFTY 500 (3 weeks and counting; last ahead the week of 2026-07-10), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 4.9 years the stock moved +114% against the NIFTY 500's +57% — ahead of the index over the full window. — as of 31 July 2026.
Will Vijaya Diagnostic Centre Ltd's share price go up?
This page publishes no price forecast for Vijaya Diagnostic Centre Ltd. What it measures instead: the share price is ₹1,344, the price is in a confirmed uptrend 12 weeks in. Its P/E of 80.0× sits at the 92nd percentile of its own 5-year range. — as of 31 July 2026.
Who owns Vijaya Diagnostic Centre Ltd?
Promoters hold 52.5% of Vijaya Diagnostic Centre Ltd, foreign institutions 11.7%, domestic institutions 31.6% and the public 4.2% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 10.1 points over 8 quarters. — as of 31 July 2026.
Does Vijaya Diagnostic Centre Ltd have too much debt?
It is moderate — Vijaya Diagnostic Centre Ltd's debt-to-equity is 0.44, and operating profit covers the interest bill 10×. FY26 borrowings were ₹423 Cr against equity of ₹957 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Vijaya Diagnostic Centre Ltd's capex?
Vijaya Diagnostic Centre Ltd spent ₹772 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹261 Cr, with ₹34.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Vijaya Diagnostic Centre Ltd's cash flow?
Vijaya Diagnostic Centre Ltd generated ₹271 Cr of operating cash flow in FY26 and ₹10.0 Cr of free cash flow after ₹261 Cr of capital spending. Reported profit that year was ₹173 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Vijaya Diagnostic Centre Ltd's profit real cash?
Yes — over the last 3 fiscal years, 155% of Vijaya Diagnostic Centre Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹271 Cr against reported profit of ₹173 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Vijaya Diagnostic Centre Ltd in its business cycle?
Vijaya Diagnostic Centre Ltd's FY26 operating margin was 41.0%, against a 9-year band of 32.0%–44.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 44.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Vijaya Diagnostic Centre Ltd story?
The sharpest disagreement: the engine is strong, but at the 92nd percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Vijaya Diagnostic Centre Ltd a stock worth studying right now?
This is not investment advice. The machine read: Vijaya Diagnostic Centre Ltd is strength at full price. The numbers are improving — and a P/E at the 92nd percentile of its own range says the market knows. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.